Stocktoria
Akzo Nobel N.V. AKZA.AS
NL · Euronext Amsterdam · XAMS · stock · Basic Materials · website
Akzo Nobel N.V. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $10.2B | $10.7B | $10.7B | $10.8B |
| Gross profit | $4.0B | $4.3B | $4.2B | $3.9B |
| R&D expense | $274.0M | $296.0M | $270.0M | $258.0M |
| SG&A expense | $1.5B | $1.6B | $1.5B | $1.5B |
| Operating income | $1.2B | $917.0M | $1.0B | $708.0M |
| Interest expense | $211.0M | $190.0M | $193.0M | $106.0M |
| Income tax | $326.0M | $246.0M | $296.0M | $214.0M |
| Net income | $635.0M | $542.0M | $442.0M | $352.0M |
| EPS (diluted) | $3.69 | $3.16 | $2.58 | $2.01 |
| Operating cash flow | $915.0M | $673.0M | $1.1B | $263.0M |
| Free cash flow | $606.0M | $367.0M | $840.0M | -$29.0M |
| Cash & equivalents | $1.6B | $1.3B | $1.5B | $1.4B |
| Inventory | $1.5B | $1.7B | $1.6B | $1.8B |
| Total assets | $14.0B | $14.2B | $14.6B | $14.7B |
| Total liabilities | $9.1B | $9.4B | $10.0B | $10.2B |
| Shareholders' equity | $4.7B | $4.6B | $4.3B | $4.3B |
Growth · year-over-year · Revenue CAGR -2.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -5.2% | +0.4% | -1.6% | — |
| Net income growth | +17.2% | +22.6% | +25.6% | — |
| EPS growth | +16.8% | +22.5% | +28.4% | — |
| Free cash flow growth | +65.1% | -56.3% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · NL · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.